The Venture Codex Logo

The Venture Codex

Delft Enterprises

Van der Burghweg 1, Delft, Zuid-Holland, 2628 CS, The Netherlands

Overview

Delft Enterprises participates in innovative, early stage and technology-based spin off companies of Delft University of Technology.

Total investments
6
Lead investments
0
Investments · 12mo
1
Active investors
0
Visit website

Investment portfolio

  • PATS

    Participated · Seed · Sep 2025

    Founded in 2018 as a spin-out from Delft University of Technology, PATS develops an integrated pest-management suite that combines computer vision, AI and nature-inspired drones to detect and neutralise flying insects in greenhouses. Its portfolio includes the PATS-C real-time flying-pest tracker, Trap-Eye sticky-trap scanner (co-developed with Biobest), and predictive software tools PATS-Vinder and PATS-Kalendar that forecast outbreaks and recommend interventions. All hardware and software are designed and manufactured in-house in Delft, enabling the company to ship more than 1,000 sensor units per month. The technology is already deployed in over 25 countries, giving vegetable, flower and ornamental growers early warnings and actionable advice while reducing labour and pesticide dependence. By replacing broad-spectrum insecticides with precise, automated solutions, PATS supports growers’ sustainability and regulatory goals. The newly raised capital will be used to speed up product development, broaden crop coverage and scale international sales, further embedding its AI platform in global greenhouse operations.

  • Innatera

    Participated · Series A · Jun 2024

    Innatera develops the Spiking Neural Processor T1, an ultra-low-power, event-driven computing platform that combines a spiking engine with a CNN accelerator and RISC-V CPU for sensor-agnostic AI in battery-powered devices. The T1 was unveiled in January 2024 and is slated to enter production later in 2024, with high-volume deliveries beginning in Q2 2025. The company says the investment will accelerate mass production to reach 1 billion devices by 2030. Innatera is led by CEO Sumeet Kumar and recently appointed Duco Pasmooij, former Apple VP, to its advisory board. The company is based in Delft, The Netherlands and raised $21M in its Series A round. Innatera develops microprocessors that mimic the brain’s processing mechanisms via a proprietary analog-mixed-signal computing architecture. The company recently launched the Spiking Neural Processor T1, which delivers signal processing and pattern recognition within a sub-milliwatt power envelope. It also offers the Talamo software development kit to simplify development of spiking neural networks. Led by CEO Sumeet Kumar, Innatera aims to scale commercial adoption of its brain-inspired chips and expand customer engagements. The company plans to use the new capital to accelerate mass production and broaden its application offerings. Financially, Innatera raised €15M in a Series A to support these go-to-market and production initiatives. Innatera develops a neuromorphic processing chip that closely mimics the brain’s pattern-recognition mechanisms to enable sensor-edge AI. The chip can process sensor data up to 100 times faster and use as much as 500 times less energy than conventional processors. Innatera targets embedding advanced AI into sensor-driven devices for applications such as intelligent speech processing in human-machine interfaces, vitals monitoring in wearables, target recognition in radars and lidars, and fault detection in industrial and automotive equipment. To commercialize its silicon, the company is building a suite of proprietary algorithms and an extensive software toolchain. The fresh €5 million seed funding will be used to hire aggressively, scale R&D, and accelerate product development to meet customer commitments through next year. The article identifies the company as a Delf-based startup and shows its co-founders as Dr. Amir Zjajo, Dr. Sumeet Kumar, and Dr. Rene van Leuken.

  • QphoX

    Participated · Equity · Jan 2024

    QphoX develops core quantum internet hardware focused on quantum transduction, translating quantum information between microwave and optical domains. The company demonstrated optical-frequency readout of superconducting qubits in October 2023 as a proof of concept. Management says its transduction hardware is at a performance level that will allow quantum systems to connect through optical quantum channels. The €8 million investment — the largest in a Dutch quantum company to date — will be used to commercialise and bring QphoX's quantum modem technology to market. The raise underscores the firm's position in the quantum networking space and provides capital to move from demonstration to productisation. QphoX is developing a commercial "quantum modem" that coherently converts electrical and microwave signals to optical signals and back so separate quantum processors can communicate. The company’s modem is designed to be agnostic to qubit type, focusing on the microwave-to-optical interface to work with superconducting and topological qubits. QphoX aims to enable networking of separate processors so quantum computers can scale beyond tens or hundreds of qubits. The modem originated at TU Delft and the company is building that academic prototype into a real product. Simon Gröblacher is CEO and co-founder. QphoX recently raised €2 million to advance product development and commercialization.

  • Villari

    Participated · Seed · Aug 2023

    Villari developed a proprietary crack-sensing system that measures local variations in the magnetic induction field to detect crack formation and monitor crack growth over time. Its solution combines custom hardware and sensing algorithms with a dashboard that lets customers view data without interrupting asset operations. The sensors are already installed at several customer sites, including bridges owned by the Dutch government and industrial cranes at harbours and steel manufacturers across Europe. Villari aims to scale commercially and expand internationally, targeting ageing bridges, cranes and other hard-to-inspect steel assets. The company is also exploring applications in the offshore wind turbine industry where accessibility and harsh environments make crack monitoring especially challenging. The team plans to grow by hiring engineers and sales talent to accelerate deployment and scaling. Villari develops a technological sensor solution and analytics to detect cracks in steel structures with high accuracy (1–10 mm) by placing sensors in strategic locations and continuously analyzing measurements with its algorithms. The system provides permanent structural health monitoring that reduces the need for costly, time-consuming inspections and enables better planning of repairs and reinforcements. The company says its technology can help safely extend the lifetime of ageing steel assets and cut CO2 emissions from premature replacements and repairs. Villari targets large owners of steel assets such as Rijkswaterstaat and industrial producers like Tata Steel. The startup is early-stage and Delft-based; it will use newly raised capital for further development, research, and team expansion. The founding team includes CEO Olivier Baas, who researched sensor physics and structural health monitoring at TNO and TU Delft, and COO Floris Achterberg, a former project manager at Roland Berger with an MSc in Transport Engineering & Logistics and an MBA from IESE.

  • Gilbert Technologies

    Participated · Seed · Jun 2023

    Gilbert Technologies, an Eindhoven-based spin-off from Delft University of Technology, develops medical inhalation devices using electrospray/electrohydrodynamic atomisation (EHDA) technology. Its core product roadmap centers on an adaptable EHDA drug-delivery platform integrated into a smart handheld precision inhaler. The company targets regional lung deposition for pulmonary administration across indications including cystic fibrosis, severe asthma, lung cancer, and pulmonary arterial hypertension. Antibiotic therapy for cystic fibrosis is its top priority for initial drug-device combinations. Gilbert is working with biopharmaceutical partners to advance anti-infective, biological, and oncological therapies using its platform. Management says the company aims to move from clinical-stage toward commercial-stage while reducing treatment burden on healthcare systems.

Team

No current team members are available.